Vistagen Therapeutics Inc. Watch

from SCHEDULE 13G Joint Filing Agreememt

from 8-K 44 pages 15,010,810 Shares of Common Stock Pre-Funded Warrants to Purchase 3,577,240 Shares of Common Stock Tranche 1 Warrants to Purchase 9,294,022 Shares of Common Stock (Or Pre-Funded Warrants in Lieu Thereof) and Tranche 2 Warrants to Purchase 11,265,086 Shares of Common Stock (Or Pre-Funded Warrants in Lieu Thereof) VistaGen Therapeutics, Inc. Underwriting Agreement

from SC 13G 1 page Joint Filing Agreement

from SC 13G 1 page Exhibit 1 Joint Filing Agreement

from 8-K 33 pages Open Market Sale Agreementsm May 14, 2021 Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen

from 8-K 39 pages 63,000,000 Shares of Common Stock 2,000,000 Shares of Series D Preferred Stock VistaGen Therapeutics, Inc. Underwriting Agreement

from 8-K 36 pages 15,625,000 Shares of Common Stock VistaGen Therapeutics, Inc. Underwriting Agreement

from 8-K 28 pages VistaGen Therapeutics, Inc. Common Stock, Par Value $0.001 Per Share Underwriting Agreement

from 8-K 26 pages VistaGen Therapeutics, Inc. 10,000,000 Shares of Common Stock Warrants to Purchase Up to 10,000,000 Shares of Common Stock Underwriting Agreement

from S-1/A 26 pages VistaGen Therapeutics, Inc. [_] Shares of Common Stock [_] Warrants to Purchase Up to [_] Shares of Common Stock Underwriting Agreement

from 8-K 23 pages VistaGen Therapeutics, Inc. 1,371,430 Shares of Common Stock Series A1 Warrants to Purchase Up to 1,388,931 Shares of Common Stock and Series A2 Warrants to Purchase Up to 503,641 Shares of Common Stock Underwriting Agreement

from 8-K 39 pages VistaGen Therapeutics, Inc. 2,352,942 Shares of Common Stock Warrants to Purchase Up to 2,352,942 Shares of Common Stock Underwriting Agreement

from S-1/A 37 pages VistaGen Therapeutics, Inc. Shares of Common Stock Warrants to Purchase Up to [ ] Shares of Common Stock Underwriting Agreement

from SC 13D 1 page Joint Filing Agreement in Accordance With Rule 13d-1(k)(1) Promulgated Under the Securities Exchange Act of 1934, the Undersigned Agree to the Joint Filing of a Statement on Schedule 13d (Including All Amendments Thereto) With Respect to the Common Stock, $0.001 Par Value, of Excaliber Enterprises Ltd. and Further Agree to the Filing of This Agreement as an Exhibit Thereto. in Addition, Each Party to This Agreement Expressly Authorizes Each Other Party to This Agreement to File on Its Behalf All Amendments to Such Statement on Schedule 13d. Date: June 13, 2011 Cato Holding Company By: /S/ Allen E. Cato Name: Allen E. Cato, M.D., PH.D. Title: Chief Executive Officer Dr. Allen E. Cato By: /S/ Allen E. Cato